A study of the drug—the prescription pain reliever salsalate—also found it reduced inflammation associated with type 2 diabetes. But it produced unwelcome side effects that could limit its potential as a diabetes treatment.
Infections that occur later don’t seem to pose as high as risk. When infants between 6 and 12 months had a respiratory illness, their risk only increased by 32 percent, the study found.
Red and processed meats that have been linked with heart disease and cancer now may be a major factor with another disease that’s epidemic in the United States — Type 2 diabetes.
A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential new strategy for treating those in the early stages of the disease, experts said.
A new, first-in-its-class drug for type 2 diabetes has just been approved by the Food and Drug Administration. Invokana works by blocking re-absorption of glucose by the kidneys and stimulating urination, which removes glucose from the bloodstream.
Today, we bring you more from the American Diabetes Association’s 73rd Scientific Sessions in Chicago, an update on the most interesting new drugs, and some stand-out research.
We have choices. Whether it’s the latest gadgets like glucose meters, insulin pumps, or continuous glucose monitors (CGMs), or different types of medications, options exist and we are fortunate enough right now to be able to tailor our D-Lives how we’d like in many respects.
Summer has arrived, meaning the year’s already half over (wow!) And along with all the diabetes conference activity underway, we’ve also had the pleasure of reading some great blog posts from across the Diabetes Online Community (DOC) this past month.
Almost two decades after the landmark Diabetes Control and Complications Trial (DCCT) ended, we are still seeing dramatic reductions in diabetes complications achieved with intensive glycemic control in the intensive control group.
Serious hypoglycemia (low blood glucose) is still prevalent in the United States. One-third of people with diabetes currently use insulin, and roughly 90% of those who use insulin have experienced hypoglycemia.
A study carried out in India examining the safety and efficacy of self-donated (autologous), transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M), has found that patients receiving the transplants, when compared to a control group of TD2M patients who did not receive transplantation, required less insulin post-transplantation.
Attia received an unpleasant medical surprise that led him to wonder: is our understanding of diabetes right? Could the precursors to diabetes cause obesity, and not the other way around?
It may be possible to reverse type 1 diabetes by training a patient’s own immune system to stop attacking their body, an early trial suggests. A study in 80 patients, published in the journal Science Translational Medicine, showed a vaccine could retrain their immune system.
A cure may not be around the corner, but scientists are hard at work on ways to replicate the functions of the pancreas. Researchers are using rodents to develop a system for targeted non-user initiated insulin delivery.
In a breakthrough clinical trial, Stanford University researchers have created a never-before-seen vaccine that utilizes modified DNA to shut down specific sections of the immune system. The vaccine has shown promising results in combatting Type 1 diabetes, potentially paving the way for brand new treatments to help individuals with the disorder.
Data presented at the American Diabetes Association (ADA) 73rd Scientific Sessions® provides insights for use of Trajenta® (linagliptin) in adults with Type 2 Diabetes (T2D) with moderate to severe renal impairment
Type 2 diabetes tends to run in families: If parents have it, children are likely to get it too. But is that because of having similar genes, or similar behaviors? Maybe it’s neither. Maybe it’s having the same kind of bacteria in their guts.
Long-awaited results from a nearly 10-year trial exploring the effect of changes in diet and exercise among people with diabetes weren’t what most people expected.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA®
In the first comprehensive trial of its kind, a study from Medtronic, Inc. showed that its advanced insulin pump can safely shut itself off when blood sugar gets too low – adjusting insulin delivery accordingly without patient intervention.